New Delhi: In a significant breakthrough for women’s healthcare, India has introduced an affordable, indigenous Human Papillomavirus (HPV) testing solution that could dramatically improve access to cervical cancer screening across the country, particularly in underserved and rural regions. The development is expected to strengthen India’s fight against cervical cancer, one of the leading causes of cancer-related deaths among women.
The newly developed HPV diagnostic kits were validated under the study titled Validation of Indigenous Human Papillomavirus Tests for Cervical Cancer Screening in India (i-HPV). Developed through collaborations supported by the Department of Biotechnology and the Biotechnology Industry Research Assistance Council (BIRAC), the tests are designed to provide accurate, rapid, and cost-effective screening while meeting international quality standards
Health experts have long identified affordability as a major barrier to cervical cancer screening in India. Conventional HPV DNA tests are often expensive and inaccessible for large sections of the population. Research indicates that screening costs can discourage participation, especially among women in low-income communities. The availability of low-cost indigenous alternatives is therefore expected to expand coverage and encourage early detection.
The indigenous HPV tests have been developed using locally available technology, including platforms originally adapted from COVID-19 RT-PCR testing systems. According to researchers, the tests can identify the most common high-risk HPV strains responsible for cervical cancer and could be integrated into national screening programmes.
Medical professionals emphasize that HPV testing is more sensitive than traditional screening methods such as Visual Inspection with Acetic Acid (VIA) and can identify high-risk infections before cancer develops. Several studies have also shown growing acceptance of HPV-based screening, particularly when combined with self-sampling options that make testing more convenient for women.
Cervical cancer remains a major public health concern in India. Most cases are linked to persistent infection with high-risk HPV strains. Experts believe that wider adoption of HPV screening, coupled with vaccination programmes and timely treatment, could significantly reduce disease burden in the coming years.
Public health officials view the launch of these indigenous test kits as a milestone in India’s efforts to eliminate cervical cancer. By reducing costs and improving accessibility, the innovation has the potential to bring life-saving screening services closer to millions of women who have historically remained outside the healthcare system.
As India advances toward nationwide cervical cancer prevention initiatives, experts say that affordable screening technologies such as these indigenous HPV tests could play a pivotal role in achieving early diagnosis, improving treatment outcomes, and ultimately saving thousands of lives each year.
